Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 18 citing articles:

Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Tatjana Radosavljević, Milica Branković, Janko Samardžić, et al.
Antioxidants (2024) Vol. 13, Iss. 8, pp. 906-906
Open Access | Times Cited: 12
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B. Patel
World Journal of Gastroenterology (2023) Vol. 29, Iss. 32, pp. 4831-4850
Open Access | Times Cited: 19
Protein Kinases in Obesity, and the Kinase-Targeted Therapy
Atilla Engin
Advances in experimental medicine and biology (2024), pp. 199-229
Closed Access | Times Cited: 6
Old age as a risk factor for liver diseases: Modern therapeutic approaches
Milena Georgieva, Charilaos Xenodochidis, Natalia Krasteva
Experimental Gerontology (2023) Vol. 184, pp. 112334-112334
Open Access | Times Cited: 13
Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management
Andrew Ndakotsu, Tagbo Charles Nduka, Simran Agrawal, et al.
Heart Failure Reviews (2025)
Closed Access
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
В. Т. Ивашкин, О. М. Драпкина, M. V. Maevskaya, et al.
Russian Journal of Gastroenterology Hepatology Coloproctology (2025) Vol. 35, Iss. 1, pp. 94-152
Open Access
Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients
Quyen Thi Tran, Tham Thi Bui, Lien Thi Ngo, et al.
CPT Pharmacometrics & Systems Pharmacology (2025)
Open Access
An Overview of the Role of Peroxisome Proliferator-activated Receptors in Liver Diseases
Zahra Changizi, Forough Kajbaf, Azam Moslehi
Journal of Clinical and Translational Hepatology (2023) Vol. 11, Iss. 7, pp. 1542-1552
Open Access | Times Cited: 10
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, et al.
Medicina (2023) Vol. 59, Iss. 10, pp. 1789-1789
Open Access | Times Cited: 9
To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases
Wen-Ling Lee, Peng‐Hui Wang, Szu‐Ting Yang, et al.
Journal of the Chinese Medical Association (2022)
Open Access | Times Cited: 14
G-Protein-Coupled Receptor 120 Agonist Mitigates Steatotic and Fibrotic Features Triggered in Obese Mice by the Administration of a High-Fat and High-Carbohydrate Diet
Simona Pompili, Alfredo Cappariello, Antonella Vetuschi, et al.
ACS Omega (2024) Vol. 9, Iss. 29, pp. 31899-31909
Open Access | Times Cited: 2
Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
André Scheen
La Presse Médicale (2022) Vol. 52, Iss. 1, pp. 104158-104158
Closed Access | Times Cited: 11
Management of Cardiovascular Risk in the Non‑alcoholic Fatty Liver Disease Setting
Paula Luque-Linero, Luis Castilla‐Guerra
European Cardiology Review (2024) Vol. 19
Open Access | Times Cited: 1
Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease
José Arriola-Montenegro, Renato Beas, Renato Cerna-Viacava, et al.
World Journal of Cardiology (2023) Vol. 15, Iss. 7, pp. 328-341
Open Access | Times Cited: 3
Targeting Mitochondria for the Prevention and Treatment of Nonalcoholic Fatty Liver Disease: Polyphenols as a Non-pharmacological Approach
Jaime Zapata, Mauricio Castro‐Sepúlveda, Sandra Soto-Alarcón, et al.
Current Medicinal Chemistry (2022) Vol. 30, Iss. 26, pp. 2977-2995
Closed Access | Times Cited: 5
Diabetes mellitus bei Patient:innen mit Leberzirrhose – eine besondere therapeutische Herausforderung
Claudia Ress
Journal für Gastroenterologische und Hepatologische Erkrankungen (2024) Vol. 22, Iss. 2, pp. 49-55
Closed Access
Metabolic Side Effects from Antipsychotic Treatment with Clozapine Linked to Aryl Hydrocarbon Receptor (AhR) Activation
Karin Fehsel
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2294-2294
Open Access
Metformin: Beyond Type 2 Diabetes Mellitus
Rahnuma Ahmad, Mainul Haque
Cureus (2024)
Open Access
Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
Chin‐Hsiao Tseng
Cancers (2023) Vol. 15, Iss. 17, pp. 4276-4276
Open Access | Times Cited: 1
Page 1

Scroll to top